We are pleased to announce the release of our latest white paper, '3D reconstructed skin models: Transforming clinical and safety testing', exploring how advanced in vitro skin and mucosal tissue systems are reshaping clinical and dermatological research.
With increasing demand for ethical, human-relevant testing methods, 3D reconstructed models, such as reconstructed human epidermis (RHE) and mucosal epithelium, are now essential tools in safety assessment, drug development and regulatory compliance. These models closely mimic human tissue structure and function, offering a scientifically robust alternative to animal testing.
As their use expands across irritation testing, neonatal skin assessment, disease modeling and bioequivalence studies, researchers must navigate both their promise and their limitations. This new white paper provides valuable insights into the current state of 3D tissue models and details their effective application within regulatory and scientific frameworks.
Download the white paper to learn about:
- The evolution of 3D skin and epithelium models: An overview of how RHE and epithelium models are advancing human-relevant, non-animal testing strategies
- Applications across dermatology and drug development: From neonatal skin to impaired barrier models, explore key use cases that support safer, more efficient product development
- Model validation and regulatory relevance: Learn how standardized protocols such as OECD guidelines ensure scientific rigor and cross-sector acceptance
- Maximizing scientific confidence: Discover how a multiparametric approach can enhance data quality and bolster product safety claims
These insights are particularly valuable for researchers, toxicologists and formulation scientists seeking to improve efficiency, minimize animal testing and comply with evolving regulatory standards.
Download '3D reconstructed skin models: Transforming clinical and safety testing
For further information, please contact:
Jennifer Buckley
Senior Global Marketing Manager
Health and Nutrition
t: +1 973 461 1498
About SGS
SGS is the world’s leading Testing, Inspection and Certification company. We operate a network of over 2,500 laboratories and business facilities across 115 countries, supported by a team of 99,500 dedicated professionals. With over 145 years of service excellence, we combine the precision and accuracy that define Swiss companies to help organizations achieve the highest standards of quality, compliance and sustainability.
Our brand promise – when you need to be sure – underscores our commitment to trust, integrity and reliability, enabling businesses to thrive with confidence. We proudly deliver our expert services through the SGS name and trusted specialized brands, including Brightsight, Bluesign, Maine Pointe and Nutrasource.
SGS is publicly traded on the SIX Swiss Exchange under the ticker symbol SGSN (ISIN CH1256740924, Reuters SGSN.S, Bloomberg SGSN:SW).
